The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Bodine P S BelderbosMirjam de WithRajbir K SinghBram C AgemaSamira El BouazzaouiEsther Oomen-de HoopRonald de WitRon H N van SchaikRon H J MathijssenSander BinsPublished in: Cancer chemotherapy and pharmacology (2020)
In this study, SLCO1B1 (SLCO1B1*15 and SLCO1B1*1B) was associated with cabazitaxel-induced adverse events in mCRPC patients. As the associations were opposite to previous studies in other drugs and contradicted an underlying pharmacokinetic rationale, these findings are likely to be false-positive and would ideally be validated with even larger (pharmacokinetic) cohorts.